Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Acquisitions & Divestments (2022 - 2025)

Tarsus Pharmaceuticals (TARS) has 4 years of Change in Acquisitions & Divestments data on record, last reported at $92.1 million in Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 159.64% year-over-year to $92.1 million; the TTM value through Dec 2025 reached $361.8 million, up 395.62%, while the annual FY2025 figure was $361.8 million, 395.62% up from the prior year.
  • Change in Acquisitions & Divestments reached $92.1 million in Q4 2025 per TARS's latest filing, down from $99.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $99.5 million in Q3 2025 and bottomed at $2.5 million in Q1 2024.
  • Average Change in Acquisitions & Divestments over 4 years is $47.3 million, with a median of $40.3 million recorded in 2023.
  • Peak YoY movement for Change in Acquisitions & Divestments: tumbled 93.8% in 2024, then soared 3548.72% in 2025.
  • A 4-year view of Change in Acquisitions & Divestments shows it stood at $5.3 million in 2022, then soared by 235.84% to $17.8 million in 2023, then surged by 98.68% to $35.5 million in 2024, then surged by 159.64% to $92.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Acquisitions & Divestments were $92.1 million in Q4 2025, $99.5 million in Q3 2025, and $79.0 million in Q2 2025.